Visium Asset Management’s Lipocine LPCN Stock Holding History

Visium Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-53,218	Closed	-$9.18M	–	427
2016 Q1	$9.18M	Sell	53,218 -4,298	-7%	-$733K	0.16%	166
2015 Q4	$12.6M	Hold	57,516	–	–	0.19%	126
2015 Q3	$11.6M	Sell	57,516 -9,308	-14%	-$2.15M	0.16%	136
2015 Q2	$9.75M	Sell	66,824 -4,117	-6%	-$511K	0.14%	161
2015 Q1	$8.32M	Hold	70,941	–	–	0.12%	172
2014 Q4	$6.34M	Hold	70,941	–	–	0.09%	203
2014 Q3	$7.37M	Buy	+70,941	New	+$8.82M	0.11%	195

Other funds holding LPCN

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Visium Asset Management's LPCN Position: Q2 2016 in Review

Visium Asset Management sold out of Lipocine (LPCN) in Q2 2016, closing a stake of 53,218 shares — an estimated $9.18M sold.

Visium Asset Management first reported a position in LPCN in Q3 2014 and held it in 7 quarters. The position peaked at $12.6M in Q4 2015. 54 funds tracked by Wall St. Rank hold LPCN as of Q2 2016.

Visium Asset Management reported no remaining Lipocine position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 53,218 Lipocine shares in Q2 2016, an estimated $9.18M.
Visium Asset Management first reported a position in Lipocine in Q3 2014 and held it in 7 quarters.
Visium Asset Management's Lipocine position peaked at $12.6M in Q4 2015.
54 funds tracked by Wall St. Rank held Lipocine as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.